Home  >  Press Releases  >  Most Recent
Share

Press Releases

Press release year list 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006
December 30, 2016
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (EST) on Thursday, Feb. 16, 2017. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review fourth quarter and full year 2016 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on Feb. 16. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. ...
December 21, 2016
First monoclonal antibody licensed to help control the clinical signs associated with atopic dermatitis in dogs Targets and neutralizes interleukin-31 (IL-31), a key itch-inducing cytokine (protein) in canine atopic dermatitis Provides convenience and long-lasting relief from itch with one injection every four to eight weeks Joins Zoetis’ APOQUEL ® (oclacitinib tablet), giving the company two targeted treatment options to offer veterinarians for canine patients with atopic dermatitis Zoetis Inc . (NYSE:ZTS) today announced that the U.S. Department of Agriculture (USDA) has granted the company a license for CYTOPOINT™, the first monoclonal antibody (mAb) therapy approved to help provide sustained control of the clinical signs associated with atopic dermatitis in dogs. CYTOPOINT targets and neutralizes interleukin-31 (IL-31), a key protein involved in triggering itch in dogs. It provides fast, effective relief of itching – the hallmark sign of the allergic skin condition atopic ...
December 13, 2016
Zoetis Inc . (NYSE:ZTS) will participate in the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 11, 2017, in San Francisco, Calif. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 1:00 p.m. EST (10 a.m. PST). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. Zoetis serves veterinarians, livestock producers ...
December 6, 2016
Company Also Declares First Quarter 2017 Dividend; Board Approves 10.5% Payment Increase Zoetis Inc. (NYSE: ZTS) today announced that its Board of Directors has authorized a $1.5 billion multi-year share repurchase program as part of its long-term capital allocation plans. The shares are expected to be repurchased at the discretion of management over a multi-year period, and the program can be cancelled at any time. The company’s previous $500 million share repurchase program, which was approved in November 2014, is expected to be completed at the end of this year. The Board of Directors also declared a first quarter 2017 dividend of $0.105 per share, an increase of 10.5% from the quarterly dividend rate paid in 2016. The dividend is to be paid on Wednesday, March 1, 2017, to holders of record of the company’s common stock on Friday, January 20, 2017. “Our consistent performance, the improvements to our cost structure, as well as the strength of our business model, have Zoetis ...
November 2, 2016
For Third Quarter 2016, Zoetis Reports Revenue of $1.2 Billion, Growing 2%, and Net Income of $239 Million, or $0.48 per Diluted Share, Growing 26% on a Reported Basis Reports Adjusted Net Income of $258 Million, or Adjusted Diluted EPS of $0.52, for Third Quarter 2016 Delivers 4% Operational Growth in Revenue and 6% Operational Growth in Adjusted Net Income, Excluding Foreign Exchange, for Third Quarter 2016 Updates Full Year 2016 Revenue Guidance to $4.850 - $4.900 Billion and Increases Diluted EPS to $1.66 - $1.75 on a Reported Basis, or $1.91 - $1.96 on an Adjusted Basis Updates Full Year 2017 Revenue Guidance to $5.150 - $5.275 Billion, with Diluted EPS of $2.10 - $2.22 on a Reported Basis, or $2.28 - $2.38 on an Adjusted Basis Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2016 and updated its guidance for full year 2016 and 2017. The company reported revenue of $1.2 billion for the third quarter of 2016, an increase of 2% compared with the ...
October 14, 2016
Zoetis Inc . (NYSE:ZTS) will participate in the 25th Annual Credit Suisse Healthcare Conference on Tuesday, Nov. 8, 2016, in Scottsdale, Ariz. Kristin Peck, Executive Vice President and President, U.S. Operations, will represent the company and respond to questions from analysts. She is scheduled to present at 3:00 p.m. EST (1:00 p.m. MST). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. Zoetis serves ...
October 6, 2016
The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a fourth quarter 2016 dividend payable to holders of the company’s common stock of $0.095 per share. The dividend is to be paid on Thursday, Dec. 1, 2016, to holders of record on Thursday, Nov. 3, 2016. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2015, the company generated annual revenue of $4.8 billion with approximately 9,000 employees. For more information, visit www.zoetis.com . DISCLOSURE NOTICES Forward-Looking Statements : This ...
September 30, 2016
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (EDT) on Wednesday, Nov. 2, 2016. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review third quarter financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on Nov. 2. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. Zoetis ...
September 27, 2016
Zoetis recognized by Working Mother Magazine for its ongoing commitment to providing colleagues with opportunities for growth, advancement and work-life balance Evelyn Ortiz, Chief Talent Officer, named Zoetis Working Mother of the Year Zoetis Inc . (NYSE:ZTS) today announced that it has been named one of Working Mother Magazine’s "100 Best Companies for Working Mothers" for the third consecutive year. The publication selects the top 100 companies in the U.S. that have demonstrated their commitment to progressive workplace programs such as flexibility, advancement, paid family leave and childcare. “Zoetis is honored to be among Working Mother Magazine’s top companies for working moms for the third year in a row,” said Roxanne Lagano, Executive Vice President and Chief Human Resources Officer at Zoetis. “We strive to create a supportive and flexible working environment that is based on colleagues living our Core Beliefs. We are proud to be recognized for our leadership in establishing ...
August 21, 2016
Zoetis Inc . (NYSE:ZTS) today announced that Glenn David, Senior Vice President of Finance Operations, has been named Executive Vice President and Chief Financial Officer (CFO), and will assume responsibility for the oversight of the company’s financial management, planning and global operations, effective immediately. As CFO, David will report directly to Chief Executive Officer Juan Ramón Alaix and become part of the Zoetis Executive Team. David will succeed Executive Vice President and Chief Financial Officer Paul Herendeen, who has resigned effective August 18, 2016, to accept the position of CFO at another public company. “Glenn has been an accomplished financial and strategic leader for Zoetis and a trusted partner to me and the entire executive team since our IPO,” said Chief Executive Officer Juan Ramón Alaix. “Glenn’s strong financial acumen, deep understanding of our company’s business operations and ability to partner with our business leaders to improve overall company ...
August 11, 2016
Zoetis Inc . (NYSE:ZTS) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 14, 2016, in New York, N.Y. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 10:30 a.m. EDT. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. Zoetis serves veterinarians, livestock producers and people ...
August 8, 2016
Purchases a pioneer in developing and manufacturing microfluidic “lab on a chip” diagnostics for veterinary point-of-care services for $80 million Adds to diagnostics portfolio with specialty test instruments and cartridges Gains pipeline of next-generation diagnostics to help veterinarians better detect, prevent and treat disease Continues to deploy capital to strengthen its pipeline to support future growth Zoetis Inc . (NYSE:ZTS) today announced that it has completed the purchase of Scandinavian Micro Biodevices , a pioneer in developing and manufacturing microfluidic “lab on a chip” diagnostic analyzers and tests for veterinary point-of- care services for $80 million. The acquisition adds to Zoetis’ complementary point-of-care diagnostics portfolio, giving the company an expanded and promising pipeline in this fast-growing segment of the animal health industry. Privately-held-Scandinavian Micro Biodevices (SMB) commercialized the first point-of-care, “lab on a chip” (LOC), ...
August 3, 2016
For Second Quarter 2016, Zoetis Reports Revenue of $1.2 Billion, Growing 3%, and Net Income of $224 Million, or $0.45 per Diluted Share, on a Reported Basis Zoetis Reports Adjusted Net Income of $246 Million, or Adjusted Diluted EPS of $0.49, for Second Quarter 2016 Zoetis Delivers 6% Operational Growth in Revenue and 22% Operational Growth in Adjusted Net Income, Excluding Foreign Exchange, for Second Quarter 2016 Zoetis Increases Full Year 2016 Revenue Guidance to $4.800 - $4.900 Billion and Diluted EPS to $1.52 - $1.63 on a Reported Basis, or $1.86 - $1.93 on an Adjusted Basis Zoetis Inc . (NYSE:ZTS) today reported its financial results for the second quarter of 2016 and increased its revenue and adjusted net income guidance for full year 2016. The company reported revenue of $1.2 billion for the second quarter of 2016, an increase of 3% compared with the second quarter of 2015. Net income for the second quarter of 2016 was $224 million, or $0.45 per diluted share, compared with a ...
June 30, 2016
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (EDT) on Wednesday, Aug. 3, 2016. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Paul Herendeen will review second quarter financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on Aug. 3. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. Zoetis ...
May 31, 2016
Six abstracts to be presented by Zoetis scientists Contributes to new understanding of interleukin-31 (IL-31) in canine atopic dermatitis and use of lokivetmab to inhibit the IL-31 pathway and help reduce clinical signs of atopic dermatitis Zoetis scientists will present six abstracts at the 8th World Congress of Veterinary Dermatology (WCVD) that contribute to the body of evidence supporting the use of lokivetmab, an antibody designed specifically for dogs that inhibits the canine cytokine interleukin-31 (cIL-31). The data also advance scientific understanding of the role of IL-31 in canine atopic dermatitis. The WCVD takes place May 31 to June 4 in Bordeaux, France. Data Supporting the Efficacy of Lokivetmab in Canine Atopic Dermatitis Zoetis will present the results of a randomized, double-blind, placebo-controlled dose determination trial to evaluate efficacy of three doses of lokivetmab (0.125, 0.5 or 2.0 mg/kg) in providing relief from the clinical signs of pruritus (itching) ...
May 18, 2016
Zoetis Inc . (NYSE:ZTS) will participate in the William Blair 36th Annual Growth Stock Conference on Tuesday, June 14, 2016, in Chicago, Ill. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 10:30 a.m. EDT (9:30 a.m. CDT). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. Zoetis serves veterinarians, livestock ...
May 16, 2016
First and only FDA-approved treatment calms without sedating Dogs that experience fear and anxiety in response to loud noise such as fireworks, thunder, and construction work now have a new treatment option with the launch of SILEO® (dexmedetomidine oromucosal gel), the first and only medication approved by the U.S. Food and Drug Administration (FDA) for treatment of noise aversion in dogs. Noise aversion refers to the behavioral and clinical signs of fear and anxiety experienced by dogs in response to noise. SILEO, which is being marketed in the U.S. by Zoetis Inc. (NYSE:ZTS), is available from veterinarians by prescription and can be safely administered at home by pet owners to help calm dogs without sedating for the duration of noise events. “We know that noise aversion has been difficult to treat, is stressful for pet owners and can be traumatic for their dogs. SILEO works the way veterinarians and pet owners need it to work, calming dogs while allowing them to interact normally ...
May 13, 2016
Zoetis Inc . (NYSE:ZTS) will participate in the Goldman Sachs 37th Annual Global Healthcare Conference on Tuesday, June 7, 2016, in Rancho Palos Verdes, Calif. Paul Herendeen, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 2:20 p.m. EDT (11:20 a.m. PDT). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of ...
May 12, 2016
The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a third quarter 2016 dividend payable to holders of the company’s common stock of $0.095 per share. The dividend is to be paid on Tuesday, Aug. 30, 2016, to holders of record on Thursday, June 30, 2016. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2015, the company generated annual revenue of $4.8 billion with approximately 9,000 employees. For more information, visit www.zoetis.com . DISCLOSURE NOTICES Forward-Looking Statements : This ...
May 12, 2016
Speaking to shareholders at the Zoetis Inc . (NYSE:ZTS) annual meeting today in Short Hills, N.J., Chief Executive Officer Juan Ramón Alaix highlighted the company’s 2015 performance and strategies for future growth as the global market leader in animal health. “In our third year as a public company, we have generated steady financial results, met our business goals and created shareholder value,” said Alaix. “This year, we are focused on several priorities, including enhancing our customers’ experience, ensuring the successful launch of new products, and advancing our R&D and business development programs to drive growth. By doing all of this, I am certain we are positioning ourselves for continued success and shareholder value creation.” Zoetis Chairman Michael McCallister presided over the business portion of the meeting and shareholder voting. Preliminary results of shareholder voting from the meeting are as follows: Juan Ramón Alaix, Paul M. Bisaro, Frank A. D’Amelio and Michael ...
May 4, 2016
For First Quarter 2016, Zoetis Delivers 12% Operational Growth in Revenue and 28% Operational Growth in Adjusted Net Income, Excluding Foreign Exchange Reported First Quarter 2016 Revenue of $1.2 Billion and Reported Net Income of $204 Million, or $0.41 per Diluted Share First Quarter 2016 Adjusted Net Income of $239 Million, or Adjusted Diluted EPS of $0.48
Updates Full Year 2016 Revenue Guidance to $4.775 - $4.875 Billion and Adjusted Diluted EPS to $1.83 - $1.90 Updates Full Year 2017 Revenue Guidance to $5.075 - $5.275 Billion and Adjusted Diluted EPS to $2.24 - $2.38 Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2016 and updated its guidance for full year 2016 and full year 2017. The company reported revenue of $1.2 billion for the first quarter of 2016, an increase of 5% compared with the first quarter of 2015. Revenue reflected an operational1 increase of 12%, excluding the impact of foreign currency. Net income for the first ...
April 28, 2016
University of Surrey and Zoetis collaborate to launch vHive, New Innovation Centre GUILDFORD, SURREY, UK - April 27, 2016 - Zoetis and the University of Surrey today launched the Veterinary Health Innovation Engine (vHive), a novel multi-disciplinary centre designed to promote the development and adoption of digital innovation in animal health. Digital technologies including wearables, apps, sensors and satellites promise to transform real-time information capture for animal owners and their veterinary advisors.  This will enable improved understanding of animal health and early identification of problems in a similar manner to eHealth for people. Furthermore, creation of digital platforms in animal health and the development of sophisticated machine-learning analytics will facilitate early warning surveillance of population threats such as the Schmallenberg virus and Bluetongue epidemics we have witnessed in recent years. Speaking at the launch, Professor Alex Cook, Head of vHive at ...
April 20, 2016
Zoetis Inc . (NYSE:ZTS) will participate in the BMO Capital Markets 11 th Annual Farm to Market Conference on Thursday, May 19, 2016, in New York, N.Y. Kristin Peck, Executive Vice President and President, U.S. Operations, will represent the company and respond to questions from analysts. She is scheduled to present at 10:10 a.m. EDT. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. Zoetis serves ...
April 7, 2016
Zoetis Inc . (NYSE:ZTS) will participate in the Deutsche Bank 41st Annual Health Care Conference on Thursday, May 5, in Boston, Mass. Paul Herendeen, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 8:40 a.m. EDT. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. Zoetis serves veterinarians, livestock ...
March 31, 2016
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (EDT) on Wednesday, May 4, 2016. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Paul Herendeen will review first quarter financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on May 4. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. Zoetis ...
March 23, 2016
Zoetis Inc . (NYSE:ZTS), the global leader in animal health, today announced that it has been named one of America’s Best Midsize Employers in 2016 by Forbes Magazine. Zoetis is the only pharmaceutical company focused solely on animal health to make the list, and is ranked #81 out of 250 midsize companies. “This honor is a terrific recognition of the workplace, culture and brand we have built at Zoetis since becoming an independent company in 2013,” said Roxanne Lagano, Executive Vice President and Chief Human Resources Officer at Zoetis. “Over the past three years, we have tried to create a supportive and flexible culture based on our colleagues living our Core Beliefs. That culture has contributed to the success and growth of our company, and we are especially proud that our colleagues and others are recommending Zoetis as a great employer.” Forbes determined its America’s Best Employers list based on an independent survey among a sample of 30,000 American employees working for ...
March 4, 2016
Zoetis Inc . (NYSE:ZTS) will participate in the Jefferies Animal Health Summit on Thursday, March 31, 2016, in New York, N.Y. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 12:00 p.m. EDT. The presentation is not scheduled to be webcast. Investors and other interested parties will be able to access the presentation materials at http://investor.zoetis.com/events-presentations at the conclusion of the event. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of ...
February 25, 2016
Easy-to-administer chewable tablet delivers fast and persistent protection over 35 days from fleas and ticks, without losing efficacy at the end of the month Innovation from Zoetis targets growing demand for oral flea and tick medication Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved Simparica TM (sarolaner) Chewables to kill adult fleas and prevent flea infestations, as well as treat and control tick infestations due to the Lone Star tick, the Gulf Coast tick, the American dog tick, and the brown dog tick. Simparica is approved for use in dogs 6 months of age or older and weighing 2.8 pounds or more. In a single-dose, tasty chewable tablet, once-monthly Simparica offers fast and persistent protection from fleas and ticks, with peak performance that lasts for a full 35 days, without losing efficacy at the end of the month.¹ “Simparica is exciting for two reasons: it acts fast to kill fleas and ticks, and it maintains its efficacy ...
February 23, 2016
First attenuated live vaccine against SRS*, ALPHA JECT LiVac® SRS, has been approved by the Chilean authorities and is available for customers in Chile. The vaccine was developed to fight the SRS disease that causes significant costs to the Chilean fish farming industry. PUERTO MONTT, CHILE - PHARMAQ's vaccine ALPHA JECT LiVac ® SRS received a provisional marketing authorisation (PMA number 2320-BP) from the Chilean authority, Servicio Agrícola y Ganadero de Chile (SAG). "Our innovative drive is based on the aquaculture industry's need to produce safe and healthy seafood. We are confident that this ground-breaking vaccine will be an important tool to help fight SRS. This is a highly requested product by the industry and will help achieve more predictable and reliable fish production,” says the President of PHARMAQ Morten Kr. Nordstad. The approval from the Chilean authority (SAG) to sell the attenuated live vaccine is a major technology milestone for the fish farming industry and for ...
February 19, 2016
The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a second quarter 2016 dividend payable to holders of the company’s common stock of $0.095 per share. The dividend is to be paid on Wednesday, June 1, 2016, to holders of record on Thursday, April 7, 2016. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2015, the company generated annual revenue of $4.8 billion with approximately 9,000 employees. For more information, visit www.zoetis.com . DISCLOSURE NOTICES Forward-Looking Statements ...
February 17, 2016
Zoetis Inc . (NYSE:ZTS) will participate in the Barclays Global Healthcare Conference on Wednesday, March 16, 2016, in Miami, Fla. Clint Lewis, Executive Vice President and President, International Operations, will represent the company and respond to questions from analysts. He is scheduled to present at 9:00 a.m. EDT. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. Zoetis serves veterinarians, ...
February 16, 2016
For Fourth Quarter 2015, Zoetis Delivers 6% Operational Growth in Revenue and 29% Operational Growth in Adjusted Net Income, Excluding Foreign Exchange Reported Fourth Quarter 2015 Revenue of $1.3 Billion and Reported Net Income of $22 Million, or $0.04 per Diluted Share Fourth Quarter 2015 Adjusted Net Income of $214 Million, or Adjusted Diluted EPS of $0.43
For Full Year 2015, Zoetis Delivers 8% Operational Growth in Revenue and 24% Operational Growth in Adjusted Net Income, Excluding Foreign Exchange Reported Full Year 2015 Revenue of $4.8 Billion and Reported Net Income of $339 Million, or $0.68 per Diluted Share Full Year 2015 Adjusted Net Income of $889 Million, or Adjusted Diluted EPS of $1.77 Updates Full Year 2016 Revenue Guidance to $4.650 - $4.775 Billion and Reaffirms Adjusted Diluted EPS of $1.71 - $1.81 Updates Full Year 2017 Revenue Guidance to $4.950 - $5.150 Billion and Reaffirms Adjusted Diluted EPS of $2.18 - $2.32 Zoetis Inc. (NYSE:ZTS) today reported its ...
January 12, 2016
Zoetis Inc. (NYSE:ZTS) provided the following statement concerning the European Commission’s decision regarding existing tax rulings in Belgium, and gave its implications for the company’s financial guidance for 2016 and 2017: Zoetis is disappointed with the European Commission’s announcement regarding Belgium’s tax rulings and its implications for Zoetis. The company complies with all tax laws and has relied on these long-standing agreements in Belgium for its financial plans and business operations, including supply chain, manufacturing, R&D and international sales organizations in Belgium. Zoetis disagrees with the decision and plans to appeal. Preliminary Update on Financial Impact to Guidance for 2016 and 2017
As a result of the decision by the European Commission, Zoetis is providing a preliminary view of its impact on Zoetis, if it is upheld on appeal. Zoetis does not expect the European Commission’s decision to have an impact on the company’s 2015 results. However, as a ...